Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
FBRX vs CGEN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CGEN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)
CGEN Overall Winner
6-Pillar Tally: FBRX 1 – 5 CGEN
Matrix Metrics: FBRX 4 – 6 CGEN
As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Forte Biosciences, Inc. (FBRX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FBRX carries a Unified Composite Score of 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin), whereas CGEN carries 49.8/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin).
- Composite vs. Pillar Nuance: While FBRX currently prints a higher short-term Unified Composite Score (52.7/100 HOLD vs. CGEN 49.8/100 HOLD), CGEN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 0.0% operating margin) and revenue trajectory (+102.1% vs. +0.0% YoY).
- Technical & Structure Timing Caution: FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About FBRX vs CGEN
FBRX
Forte Biosciences, Inc. Common Stock
$76.99
+0.03% 1D
Market Cap
$1.6B
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.09β · 3% Vol
Unified Composite Score
52.7
HOLD
Tech 49.0
Fund 51.0
Flow 62.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
CGEN
Head-to-Head Winner
Compugen Ltd
$2.02
-0.98% 1D
Market Cap
$193.2M
TTM Revenue
$76M
Forward P/E
12.4x
Beta / 30D Vol
1.44β · 62% Vol
Unified Composite Score
49.8
HOLD
Tech 53.0
Fund 52.0
Flow 55.0
Mom 64.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (FBRX 1 – 5 CGEN)
1. Valuation Multiples
CGEN
Forward P/E
N/M
12.4x
Trailing P/E
N/M
5.2x
PEG Ratio
N/M
1.29x
EV / Revenue
N/M
2.5x
2. Growth & Scale
CGEN
Revenue Growth (YoY)
+0.0%
+102.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$76M
Market Cap
$1.6B
$193.2M
3. Profitability & Quality
CGEN
Gross Margin
N/A
86.2%
Operating Margin
0.0%
41.3%
Net Profit Margin
0.0%
47.9%
Return on Equity (ROE)
-62.3%
57.2%
4. Balance Sheet & Cash Flow
CGEN
Cash Generation (TTM)
-$72M
$32M EBITDA
Cash Flow Margin
N/A
41.9% EBITDA Mgn
Net Cash / Leverage
$7.52 Book/Sh · -62.3% ROE
$4.3M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
FBRX
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
11.1% (3rd %ile)
89.7% (57th %ile)
Put/Call OI Skew
0.77x (Call-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
CGEN
OpEx & R&D Intensity
N/A
44.9% of Rev ($34M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
High-Margin Pricing Power Moat
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: FBRX (4) vs CGEN (6)| Institutional Metric | FBRX | CGEN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.6B | $193.2M | FBRX | |
| Trailing P/E Ratio | N/M | 5.2x | CGEN | |
| Forward P/E Ratio | N/M | 12.4x | CGEN | |
| Revenue Growth (YoY) | +0.0% | +102.1% | CGEN | |
| Operating Margin (TTM) | 0.0% | 41.3% | CGEN | |
| Net Profit Margin | 0.0% | 47.9% | CGEN | |
| Return on Equity (ROE) | -62.3% | 57.2% | CGEN | |
| 52-Week Range Position | 100% ($10–$77) | 33% ($1–$3) | FBRX | |
| Beta / 30D Volatility | 1.09β · 3% Vol | 1.44β · 62% Vol | FBRX | |
| Unified Institutional Score | 52.7 / 100 (HOLD) | 49.8 / 100 (HOLD) | FBRX | |
| Trailing 12M Revenue (USD) | N/A | $76M | Scale | |
| Gross Profit Margin (TTM) | N/A | 86.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | 1.29x PEG · 2.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$72M ($7.52 Book/Sh · -62.3% ROE) | $32M EBITDA ($4.3M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CGEN +25.22 pp
3M Horizon
FBRX +255.69 pp
6M Horizon
FBRX +109.35 pp
1Y Horizon
FBRX +373.63 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FBRX Revenue | CGEN Revenue | FBRX Op. Margin | CGEN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $20M | $20M | -254.2% | -130.5% | CGEN |
| FY2019 | $0M | N/A | -11288.9% | N/A | FBRX |
| FY2020 | N/A | $0M | N/A | -1574.8% | CGEN |
| FY2021 | N/A | $10M | N/A | -584.6% | CGEN |
| FY2022 | N/A | $10M | N/A | -471.7% | CGEN |
| FY2023 | N/A | $30M | N/A | -38.8% | CGEN |
| FY2024 | N/A | $30M | N/A | -53.4% | CGEN |
| FY2025 | N/A | $70M | N/A | 43.1% | CGEN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
FBRX
UNCLASSIFIED
Current IV
11.1%
IV Percentile
3rd %ile
Put/Call OI Skew
0.77x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact FBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CGEN
BREAKDOWN
Current IV
89.7%
IV Percentile
57th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
FBRX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CGEN Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
44.9% of Rev ($34M)
90D Engineering Disclosures
0 Published
Investor FAQ FBRX vs CGEN Key Questions & Quantitative Answers
As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Forte Biosciences, Inc. (FBRX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FBRX carries a Unified Composite Score of 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin), whereas CGEN carries 49.8/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin). Composite vs. Pillar Nuance: While FBRX currently prints a higher short-term Unified Composite Score (52.7/100 HOLD vs. CGEN 49.8/100 HOLD), CGEN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 0.0% operating margin) and revenue trajectory (+102.1% vs. +0.0% YoY). Technical & Structure Timing Caution: FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CGEN leads the Growth & Scale pillar: FBRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CGEN at +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FBRX cumulative revenue shifted N/A while CGEN shifted +250.0%. In operating R&D and SG&A reinvestment, FBRX deploys N/A (0 90-day corporate R&D disclosures) versus 44.9% of Rev ($34M) (0 disclosures) for CGEN.
CGEN screens cheaper on headline valuation multiples. FBRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FBRX (-62.3% ROE) versus CGEN (57.2% ROE) capital efficiency.
In options market volatility and institutional positioning, FBRX carries 11.1% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 3% Vol realized risk). By comparison, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CGEN vs FBRX · Reverse Pair
FBRX vs KRSA
· Sector Peer
FBRX vs DMRA
· Sector Peer
CGEN vs VCYT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking